ALS drug will be pulled from US market after study showed patients didn't benefit

  • 📰 wjxt4
  • ⏱ Reading Time:
  • 22 sec. here
  • 4 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 63%

Health News

Washington News,Business

The maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market.

Man dies after his car collides with tractor-trailer on I-295 near Old St. Augustine Road; speed a possible factor: FHPFILE - This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a drug for Lou Gehrigs disease that recently failed in a large study said Thursday, April 4, 2024 it will pull the medicine from the U.S. market, acknowledging it didn't help patients with the deadly neurological condition.

The company's voluntary action resolves what could have been a major dilemma for the FDA. The agency's regulators would not have had a clear path to quickly force the drug from the market if the company had refused to remove it. That's because the FDA granted the drug full approval, despite the preliminary nature of the company's data on effectiveness.by some of the agency’s own internal scientists.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 246. in CA

Canada Canada Latest News, Canada Canada Headlines